NCT07063316View on ClinicalTrials.gov

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

Active, not recruitingOBSERVATIONAL
Enrollment

15,000

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Chronic Kidney Disease
Interventions
DRUG

SGLT2 inhibitor

SGLT2 inhibitor

Trial Locations (1)

1416017

Nippon Boehringer Ingelheim Co ., Ltd., Tokyo

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY